Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 3 clinical study titled ‘Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease.’ The study aims to evaluate the effectiveness, safety, and tolerability of maridebart cafraglutide compared to a placebo in reducing body weight among adults with obesity in Japan. The primary objective is to demonstrate the drug’s superiority over placebo in achieving significant weight loss.
The intervention being tested is maridebart cafraglutide, a drug administered subcutaneously in varying doses. It is designed to aid in weight reduction and is being compared against a placebo to assess its efficacy.
The study follows a randomized, double-blind, placebo-controlled design with a parallel intervention model. Both participants and investigators are blinded to the treatment allocation, ensuring unbiased results. The primary purpose of the study is treatment-focused.
The study began on June 13, 2025, with the latest update submitted on August 6, 2025. These dates are crucial as they mark the progress and current status of the study, which is still recruiting participants.
For investors, the successful outcome of this study could positively impact Amgen’s stock performance by potentially introducing a new obesity treatment to the market. This development could enhance Amgen’s competitive position in the pharmaceutical industry, particularly in the obesity treatment segment.
The study is ongoing, and further details are available on the ClinicalTrials portal.